Greenhaven Backs Avantor to Capture the Next Cycle in Life Sciences

Greenhaven Associates has initiated a new position in Avantor (NYSE:AVTR), acquiring 18,311,570 shares valued at an estimated $228.53 million, which constitutes 4.42% of the fund's assets under management. This significant investment comes after Avantor's stock experienced a 48.2% decline over the past year, suggesting Greenhaven's conviction that the recent slowdown in lab spending may be abating. Avantor, a global provider of mission-critical products and services to the life sciences and healthcare industries, is noted for its stable, recurring revenue streams from consumables, positioning it for a potential rebound as research activity recovers.

Analysis

Greenhaven Associates has initiated a substantial new position in Avantor (AVTR), acquiring 18,311,570 shares valued at an estimated $228.53 million, representing 4.42% of the fund's AUM. This significant investment, disclosed in a Form 13F filing for Q3 2025, signals a notable conviction from a major institutional investor. The move comes despite Avantor's stock having declined 48.2% over the past year, underperforming the S&P 500 by 67.88 percentage points.

Avantor operates as a global provider of mission-critical products and services to the life sciences and healthcare sectors, characterized by a steady base of recurring revenue primarily from consumables. Greenhaven's investment suggests a belief that the recent slowdown in lab spending, which contributed to AVTR's underperformance, may be easing. The fund likely views Avantor as a reliable operator positioned to benefit from a rebound in research activity.

The investment thesis hinges on Avantor's ability to capitalize on returning lab demand and execute on cost discipline, which could lead to stronger profits and cash flow. Its consistent revenue from consumables provides a defensive characteristic, potentially enabling a faster and stronger stock rebound. However, the stock's significant underperformance indicates underlying challenges that would need to be overcome for this thesis to materialize.

Key Decisions for Investors

• Consider Avantor (AVTR) as a potential recovery play, given Greenhaven's significant new position despite recent stock underperformance.
• Monitor indicators of a rebound in global lab spending and the broader healthcare supply chain, as these are critical for Avantor's performance.
• Evaluate Avantor's operational execution on cost discipline and its ability to translate recurring revenue into improved profitability and cash flow.